Welcome to our dedicated page for Astrazeneca Plc SEC filings (Ticker: AZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding ´¡²õ³Ù°ù²¹´Ü±ð²Ô±ð³¦²¹â€™s labyrinth of R&D updates, patent expirations, and global revenue notes can feel overwhelming. Each disclosure—from breakthrough oncology trial results to collaborative milestone payments—adds pages of technical detail investors must sift through to gauge pipeline risk and earnings power.
Our platform removes that friction. Instantly surface what matters in an AstraZeneca quarterly earnings report 10-Q filing, see every AstraZeneca 8-K material events explained, and monitor AstraZeneca insider trading Form 4 transactions in real time. Stock Titan’s AI reads the fine print, producing plain-English summaries that clarify revenue by therapy area, pending FDA decisions, and cash-flow impacts. Whether you need an AstraZeneca annual report 10-K simplified or want understanding AstraZeneca SEC documents with AI, our expert analysis highlights segment performance, clinical trial spend, and tax considerations without the jargon.
Stay ahead of market-moving disclosures: receive alerts on every AstraZeneca Form 4 insider transactions real-time, explore AstraZeneca earnings report filing analysis for quarter-over-quarter trends, and review the AstraZeneca proxy statement executive compensation to see how bonuses align with pipeline milestones. From income-statement line items to drug-approval catalysts, each filing is linked, searchable, and updated the moment it posts to EDGAR. Make informed decisions faster—no graduate degree in biochemistry required.
AstraZeneca reported its total voting rights and issued share capital. The company states that as at 31 August 2025 there are 1,550,692,963 ordinary shares of US$0.25 each carrying voting rights, with no shares held in treasury. This figure is presented so shareholders can use it as the denominator to determine whether they must notify changes in their holdings under the UK Disclosure and Transparency Rules.
The notice is a routine transparency disclosure and does not include financial results, transactions, or changes to capital structure beyond the voting‑rights count.
H1 2025 results: Total revenue rose 11% CER to $28.0 bn, led by Oncology (+16%) and BioPharmaceuticals. Product Sales were $26.7 bn (+10%), Alliance Revenue $1.3 bn (+38%). Core EPS reached $4.66 (+17%) and reported EPS $3.46 (+32%) as core operating profit advanced 13%.
Q2 2025: Revenue grew 11% CER to $14.5 bn; core EPS $2.17 (+12%). Gross margin 83%; reported operating margin 24% (core 32%). Key brands outperformed: Tagrisso $3.5 bn (+10%), Imfinzi $2.7 bn (+21%), Enhertu $1.3 bn (+38%) while Soliris (-30%) and Brilinta (-21%) declined.
Capital allocation & strategy: Interim dividend increased 3% to $1.03. AZN acquired cell-therapy firm EsoBiotec for up to $1 bn, signed a $110 m upfront AI-drug-discovery deal with CSPC (milestones up to $5.2 bn) and announced a $50 bn US manufacturing/R&D investment, including a new Virginia drug-substance plant.
R&D momentum: 12 positive Phase III readouts (e.g., baxdrostat BaxHTN, Tagrisso FLAURA2) and 19 approvals. Pipeline breadth reinforced by oncology, CVRM and rare-disease advances.
Guidance reaffirmed: 2025 total revenue to grow high-single-digits and core EPS low-double-digits (CER); FX now seen broadly neutral. Core tax rate 18-22%.
FAQ
What is the current stock price of Astrazeneca Plc (AZN)?
What is the market cap of Astrazeneca Plc (AZN)?
